SCIENTIFIC REPORT Institut national du cancer 52, avenue André Morizet 2018 92100 Boulogne-Billancourt France Tél. +33 (1) 41 10 50 00 2018 - ACTIONS SCIENTIFIC REPORT SCIENTIFIC FOR CANCER RESEARCH For more information e-cancer.fr RAPCSANG19 SCIENTIFIC REPORT 2018 1ACTIONS FOR CANCER RESEARCH SCIENTIFIC REPORT 2018 2ACTIONS FOR CANCER RESEARCH The French National Cancer Institute is the health and science agency in chage of cancer control. 52, avenue André Morizet 92100 Boulogne-Billancourt France Tel. +33 (0) 1 41 10 50 00 [email protected] This document should be cited as: © Scientific report 2018, INCa, septembre 2019 This document is published by the French National Cancer Institute, which holds the rights. The information contained in this document may be reused if : 1) their reuse falls within the scope of Law Nº 78-753 of 17 July 1978 as amended, 2) this information is not altered and their meaning distorted, 3) their source and the date of their last update are mentioned. Published by the French National Cancer Institute All rights reserved – Siren 185 512 777 Conception : INCa This document was published in September 2019. It is availabled at the following address: Realised by Desk (www.desk53.com.fr) Institut national du cancer (INCa) ISBN : 978-2-37219-494-5 Direction de la recherche 52, avenue André Morizet – 92100 Boulogne-Billancourt ISBN net : 978-2-37219-495-2 e-cancer.fr © 2019. Institut national du cancer (INCa) DEPÔT LÉGAL SEPTEMBRE 2019 French National Cancer Institute /SCIENTIFIC REPORT / 2018 2018 / SCIENTIFIC REPORT / French National Cancer Institute INTRODUCTION ACTIONS FOR CANCER RESEARCH SCIENTIFIC REPORT 2018 n 2018, concrete and major progress was achieved in all areas of cancer control: prevention, screening, care, quality of life and research. THE FRENCH NATIONAL CANCER INSTITUTE pur- I sued its efforts to make innovation accessible to as many people as possible. This Scientifi c Report outlines all research initiatives in oncology, detailing the resources deployed and implemented. This report is a key element used by Scientifi c Advisory Board members to review the actions under- taken and subsequently advise and guide the Institute during its structuring processes and its initiatives. The structure of this document is intended to pro- vide both a better refl ection of the Scientifi c Advisory Board's advices and a focus placed on the recommendations of the 2014-2019 Cancer Control Plan, which will enter its fi nal year. The French National Cancer Institute is without doubt indeb- ted to all of the participating members, and we were delighted to welcome new members this year. ALONGSIDE RESEARCH ACTIONS AND INITIATIVES, this year, we have fi na- lised the regionalisation of screening schemes, and contributed to the publication of the decree authorising the extension of cervical cancer screening. In order to improve the quality, safety and relevance of care, ambitious work to modernise the cancer treatment activity authorisation scheme was initiated in 2018. The French National Cancer Institute has proposed to introduce additional quality cri- teria, in particular to facilitate access to innovation, to better defi ne technical plat- forms and grading of care, and to promote cooperation between stakeholders. Nearly 900 health facilities are until now authorised to treat cancer. EVEN THOUGH OUR PRIORITY IS TO CURE, quality of life is a major endpoint for patients and is part of their recovery process. Therefore, it is key to support patients in all aspects of the disease, whether these are psychological, econo- mic, and social. In this context, the right to be forgotten has been a major step forward and the involvement of the French National Cancer Institute has enabled an extension of this scheme to other long-term remission patients suffering from certain leukaemias, kidney and prostate cancers. THESE ADVANCES ARE THE FRUIT of combined efforts and are intended to be Professor Norbert Ifrah, MD enduring. We are committed to continuing them in 2019 and beyond, with all of ■ Chairman and CEO of the our partners. French National Cancer Institute 2018 / SCIENTIFIC REPORT / French National Cancer Institute 3 TABLE OF CONTENTS ACTIONS FOR CANCER RESEARCH SCIENTIFIC REPORT 2018 Introduction 03 Key fi gures 06 The international 1 scientifi c advisory board 8 2018 cancer research 2 activity report 14 4 French National Cancer Institute / SCIENTIFIC REPORT / 2018 Strategic topics for 3 advancing cancer research 102 4 Appendices 116 2018 / SCIENTIFIC REPORT / French National Cancer Institute 5 KEY FIGURES ACTIONS FOR CANCER RESEARCH SCIENTIFIC REPORT 2018 In 2018, INCa launched and operated 13 calls for research proposals ITMO Cancer- Aviesan launched 1,019 146 and operated projects submitted projects funded 5 calls for research proposals: projects reviewers 358 submitted 826 involved in the scientifi c review of the programmes including projects 80 funded 570reviewers international involved in the reviewers scientifi c review of the 456 programmes including international 405 reviewers 6 French National Cancer Institute / SCIENTIFIC REPORT / 2018 2018 multi-year cancer funding by programme type (INCa, DGOS and ITMO Cancer-Aviesan): €106.26M invested 4% €3.95M 20% €21.07M 19% €20.54M Investigator-driven projects Strategic research initiatives/thematic programmes 48% Platforms, resources, €50.37M infrastructures Research training / % young teams of 16 excellence €16.99M 29% Total investments €31.39M Clinical Biology and basic sciences over the 2007- 8% Translational €8.34M HSS-E-PH 2018 period: 4% €3.97M €454M in biology and basic sciences €260M 2007-2018 multi-year cancer funding in translational by programme type (INCa, DGOS and ITMO and integrated Cancer-Aviesan): €1.15Bn invested cancer research 3% €39M 22% €247M 22% € €255M 318M Investigator-driven projects in clinical Strategic research initiatives/thematic research programmes 50% Platforms, resources, €547M infrastructures Research training / € young teams of excellence 17% 119M 25% €199M in research in €286M Clinical human and Biology and basic sciences social sciences, 7% Translational 4% €84M HSS-E-PH epidemiology and €44M public health 2018 / SCIENTIFIC REPORT / French National Cancer Institute 7 1 ● The international scientific advisory board members 10 ● 2018 recommendations 11 8 French National Cancer Institute / SCIENTIFIC REPORT / 2018 The international scientifi c advisory board his 13th report to INCa’s international Scientific Advisory Board (SAB) reviews actions carried out both by INCa and Aviesan’s Multi- Organisation Thematic Institute for Cancer (ITMO Cancer-Aviesan). This report is the key element for SAB members to review the actions T undertaken and subsequently advise and guide the Institute during its structuring processes and its initiatives. Composed of internationally renowned experts and appointed by the supervising Ministers, INCa’s Scientific Advisory Board has been chaired by Prof. Catherine Lacombe since 2018. With regard to the Institute’s powers and missions, the Scientific Advisory Board: ● Ensures that INCa’s scientific and medical policy is consistent; ● Reviews INCa’s annual scientific report before it is presented to the Board of Directors; ● Makes recommendations and provides opinions on INCa’s scientific strategies and their implementation. The first part of this report is focused on the 2018 recommendations of INCa’s SAB. The SAB’s recommendations are central to the Institute establishing an action plan and proposing a strategy to handle cancer research challenges over the years. Appendix 1 summarises previous key recommendations and describes the actions conducted to implement novel initiatives and/or to reinforce the major existing programmes. 2018 / SCIENTIFIC REPORT / French National Cancer Institute 9 The international scientifi c advisory 1 board THE INTERNATIONAL SCIENTIFIC ADVISORY BOARD MEMBERS The members of the Scientifi c Advisory Board are: ● Dr. Geneviève Almouzni, PhD, Institut Curie, ● Ms. Estelle Lecointe-Artzner, Founder and Paris, France Chairperson of the Association Info Sarcomes, ● Prof. Cécile Badoual, MD, PhD, Hôpital Européen Rennes, France Georges Pompidou, Paris, France ● Dr. Douglas R. Lowy, MD, NCI Acting Director, ● Dr. Jean-Pierre Bizzari, MD, Celgene, Summit, Bethesda, USA USA ● Prof. Marc-André Mahé, MD, PhD, General ● Prof. Cédric Blanpain, MD, PhD, Université Libre Director, Centre François Baclesse, Caen, France de Bruxelles, Brussels, Belgium ● Dr. Bernard Malissen, PhD, Centre ● Ms. Dominique David, Founder and Chairperson d’Immunologie de Marseille-Luminy, Marseille, of the Association pour la recherche sur les France tumeurs cérébrales, Aix en Provence, France ● Prof. Dame Theresa Marteau, PhD, University of ● Prof. Johann de Bono, MD, PhD, The Institute Cambridge, Cambridge, United-Kingdom of Cancer Research and the Royal Marsden, ● Dr. Patrick Mehlen, PhD, Centre de recherche en London, United-Kingdom cancérologie de Lyon, Lyon, France ● Prof. Olivier Delattre, MD, PhD, Institut Curie, ● Prof. Stefan Pfi ster, MD, German Cancer Paris, France Research Centre (DKFZ), Heidelberg, Germany ● Prof. Anne Eichmann, PhD, Yale School of ● Prof. Louise POTVIN, PhD, Institut de recherche medicine, New Haven, USA en santé publique de l’Université de Montréal, ● Dr. Elizabeth A. Eisenhauer, MD, Queen’s Université de Montréal, Montréal, Canada University, Kingston, Canada ● Prof. Gérard Socié, MD, PhD, Hôpital Saint Louis, ● Prof. Yann Gauduel, PhD, Ecole Polytechnique - Paris, France